Dr Samarasinghe on the Feasibility of First-Line Blinatumomab in Down Syndrome B-ALL

Sujith Samarasinghe, MD, discusses key results from the phase 2 ALLTOGETHER 1 DS trial in Down Syndrome B-cell acute lymphoblastic leukemia.

Sujith Samarasinghe, MD, consultant pediatric hematologist, Great Ormond St. Hospital, discusses key results from the phase 2 ALLTOGETHER 1 DS trial evaluating the use of first-line blinatumomab (Blincyto) as chemotherapy replacement for patients with Down Syndrome B-cell acute lymphoblastic leukemia (B-ALL) that were presented at the 2024 EHA Hybrid Congress.